Condition: CLL/SLL · Sponsor: Ascentage Pharma Group Inc.
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.
This description comes directly from the study's public registry record.
Laura Glass · 301-520-5964 · Laura.Glass@ascentage.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Novant Health | Charlotte, North Carolina, United States | Recruiting |
| Gabrail Cancer Center | Canton, Ohio, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Swedish Health | Seattle, Washington, United States | Recruiting |
| Princess Alexandria Hospital | Brisbane, Queensland, Australia | Recruiting |
| Frankston Private Hospital | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04215809